Melphalan hydrochloride is a prescription drug used to treat multiple myeloma in certain adults. Find out how you may be able to lower your costs and more.

Melphalan Injection prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and Melphalan Injectionside effects.

The researchers observed numerical differences consistently favoring the melphalan/HDS arm vs BAC in exploratory analyses of efficacy end points (median overall survival, 18.5 vs 14.5 months ...

Melphalan 100 mg/m 2 was administered intravenously on days 1 to 2. ASCT was performed on day 4. The primary end point (complete response) was defined as no emesis and no rescue therapy within 120 ...

Therapy with melphalan plus prednisone, which has been the standard of care for patients with newly diagnosed multiple myeloma for more than 40 years, 1,2 is associated with a median survival of ...

Melphalan–prednisone (MP) has long been the treatment of choice for patients with multiple myeloma who are older than 65 years of age. 1 The introduction of new agents in the past few years has ...

Melphalan is a chemotherapy agent, prescribed for multiple myeloma, melanoma, and ovarian carcinoma. Melphalan Interaction with 50 drugs. Find out more in the list below: ...

The patients were randomly assigned to receive melphalan and prednisone (52 patients) or vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (49 patients). Patients were stratified ...

Melphalan Hydrochloride for Injection should not be used in patients whose disease has demonstrated prior resistance to this agent. Patients who have demonstrated hypersensitivity to melphalan ...

June 13, 2011 (London, United Kingdom) — Contrary to expectation, progression-free survival in patients with multiple myeloma is longer in patients who receive high-dose melphalan (Alkeran ...

Melphalan(Alkeran) generic is a chemotherapy agent, prescribed for multiple myeloma, melanoma, and ovarian carcinoma. It stops or slows the growth of cancer cells in the body.

A comparison of melphalan and prednisone with/without bortezomib in untreated myeloma patients ineligible for high-dose therapy plus stem-cell transplantation was investigated. What were the outcomes?